Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
ADAMAS PHARMACEU RG (NQ: ADMS)
28.20 USD  +0.07 (+0.25%)
Official Closing Price  /  Updated: 8:00 PM EDT, Apr 24, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 948,354
Open 28.30
Bid (Size) 28.00 (200)
Ask (Size) 28.29 (200)
Prev. Close 28.13
Today's Range 27.87 - 28.76
52wk Range 13.50 - 44.00
Shares Outstanding 26,807,221
Dividend Yield N/A
Performance
YTD
-20.90%
-20.90%
1 Month
+15.57%
+15.57%
3 Month
-33.88%
-33.88%
6 Month
+55.54%
+55.54%
1 Year
+77.92%
+77.92%
Top News
More News
Adamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia
Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced positive data from EASE LID 2, the company’s two-year Phase 3 open-label study of GOCOVRI™ (amantadine) extended release capsules, the first... Read More
from GlobeNewswire News Releases
Analysis: Positioning to Benefit within Addus HomeCare, Adamas Pharmaceuticals, ManTech International, Yintech Investment, GRIDSUM HOLDING, and Blucora — Research Highlights Growth, Revenue, and Conso
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Addus HomeCare Corporation... Read More
from GlobeNewswire News Releases
More News
Read More
Adamas Announces Multiple Data Presentations at the American Academy of Neurology Annual Meeting
from GlobeNewswire News Releases
Adamas Pharmaceuticals Shows Rising Price Performance With Jump To 83 RS Rating
from Investor's Business Daily
Advanced Distribution Management System (ADMS) – Global Industry Size, Share, Trends, Analysis and Forecast 2018 – 2025
category AP , Wire 2 , Wire 1 , and 2 more.
from Press Release Distribution Service
Adamas Pharmaceuticals Trying To Close In On Key Technical Benchmark
from Investor's Business Daily
Adamas Announces First Patient Enrolled in Phase 3 Trial of ADS-5102 in Multiple Sclerosis Patients with Walking Impairment
from GlobeNewswire News Releases
Adamas Pharmaceuticals Shows Improved Relative Price Performance; Still Shy Of Benchmark
from Investor's Business Daily
Adamas Pharmaceuticals Shows Rising Relative Strength; Still Shy Of Key Threshold
from Investor's Business Daily
Pre-Market Technical Scan on Generic Drugs Equities -- Adamas Pharma, Agile Therapeutics, Catalent, and Diplomat Pharmacy
from PR Newswire
BRIEF-Adamas Announces Final Results From Phase 3 Open-Label Study Of Gocovri
category companyNews
from Reuters: Company News
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial